home / stock / bmndf / bmndf news

BMNDF News and Press, Biomind Labs

Stock Information
Company Name: Biomind Labs
Stock Symbol: BMNDF
Market: OTC
Website: biomindlabs.com
Menu
BMNDF BMNDF Quote BMNDF Short BMNDF News BMNDF Articles BMNDF Message Board
Get BMNDF Alerts

News, Short Squeeze, Breakout and More Instantly...
BMNDF - Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways

TORONTO, ON / ACCESSWIRE / July 18, 2024 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI) , a leading biotech company dedicated to developing the next-generation of pharmaceuticals targeting the root causes of neurological disorders, announced the ...
BMNDF - Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's Disease

Biomind Labs Inc. (“ Biomind ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeti...

BMNDF - Biomind Labs Provides Corporate Update

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMNDF - Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...
BMNDF - Biomind Announces Voting Results From the 2023 Annual Meeting of Shareholders

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMNDF - Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer's Disease With a Proprietary formulation Based On 5-MeO-DMT

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMNDF - Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax(TM)

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...
BMNDF - Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer's Disease

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric...

BMNDF - Biomind Labs Announces FDA Investigational New Drug Clearance for Its New Chemical Entity Triptax(TM) Targeting Treatment-Resistant Depression and Reports Third Quarter Financial Results

Controlling shareholder provides loan facility Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of ph...

BMNDF - Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...
Next 10